Sub Banner Image

Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside

Market Impact

Vandana Singh

·

May 7, 2025

·

Benzinga

Chardan initiates Praxis with a Buy rating, highlighting its epilepsy pipeline, strong cash position, and billion-dollar potential of vormatrigine.

Latest Ratings for PRAX

DateFirmActionFromTo
Dec 2021HC Wainwright & Co.Initiates Coverage OnBuy
Aug 2021B of A SecuritiesInitiates Coverage OnBuy
Apr 2021William BlairInitiates Coverage OnOutperform

View More Analyst Ratings for PRAX

View the Latest Analyst Ratings

read more

More from

Benzinga

More

Market Impact

Articles

Trending News

Enjoy premium content in your inbox.

You're in! Check your email to learn more.
Oops! Something went wrong while submitting the form.